<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413567</url>
  </required_header>
  <id_info>
    <org_study_id>C-20000 A &amp; B</org_study_id>
    <nct_id>NCT02413567</nct_id>
  </id_info>
  <brief_title>Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fractyl Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fractyl Laboratories, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Fractyl Duodenal Mucosal Resurfacing (DMR)
      Procedure for the treatment of Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2015</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean reduction in HbA1c (glycated hemoglobin) from baseline at 24 weeks post-procedure</measure>
    <time_frame>24 weeks post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)</measure>
    <time_frame>24 weeks post-procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DMR Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the endoscopic DMR procedure in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DMR Procedure (Fractyl)</intervention_name>
    <description>Endoscopic procedure</description>
    <arm_group_label>DMR Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. 28 -75 years of age

          2. Diagnosed with Type 2 Diabetes for less than 10 years

          3. HbA1c of 7.5 - 10.0% (59-86 mmol/mol)

          4. Body Mass Index (BMI) ≥ 24 and ≤ 40 kg/m2

          5. On a minimum of 1 stable oral anti-diabetic medications with no changes in medication
             in the previous 3 months prior to study entry

          6. Willing to comply with study requirements and able to understand and comply with
             informed consent

          7. Sign an informed consent form

        Exclusion Criteria

          1. Diagnosed with Type 1 Diabetes or with a history of ketoacidosis

          2. Probable insulin production failure, defined as fasting C Peptide serum &lt;1ng/mL
             (333pmol/l)

          3. Current use of Insulin

          4. Use of Glucagon like peptide (GLP)-1 analogues

          5. Hypoglycemia unawareness or a history of severe hypoglycemia (at least 1 severe
             hypoglycemic event, as defined by need for third-party-assistance, in the last year)

          6. Known autoimmune disease, as evidenced by a positive anti glutamic acid decarboxylase
             (GAD) test, including Celiac disease, or pre-existing symptoms of systemic lupus
             erythematosus, scleroderma or other autoimmune connective tissue disorder

          7. Previous gastrointestinal (GI) surgery that could affect the ability to treat the
             duodenum such as subjects who have had a Bilroth 2, Roux-en-Y gastric bypass, or other
             similar procedures or conditions

          8. History of chronic or acute pancreatitis

          9. Known active hepatitis or active liver disease

         10. Symptomatic gallstones or kidney stones, acute cholecystitis or history of duodenal
             inflammatory diseases including Crohn's Disease and Celiac Disease

         11. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers,
             gastric varices, strictures, congenital or acquired intestinal telangiectasia

         12. Use of anticoagulation therapy (such as Warfarin) which cannot be discontinued for 7
             days before and 14 days after the procedure

         13. Use of P2Y12 inhibitors (clopidrogel, pasugrel, ticagrelor) which cannot be
             discontinued for 14 days before and 14 days after the procedure. Use of aspirin is
             allowed.

         14. Unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during treatment
             through 4 weeks post procedure phase

         15. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide)

         16. Receiving weight loss medications such as Meridia, Xenical, or over the counter weight
             loss medications

         17. Persistent Anemia, defined as Hgb &lt; 10 mg/dl

         18. Estimated glomerular filtration rate (eGFR) or Modification of Diet in Renal Disease
             (MDRD) &lt;30 ml/min/1,73m^2

         19. Active systemic infection

         20. Active malignancy within the last 5 years

         21. Not potential candidates for surgery or general anesthesia

         22. Active illicit substance abuse or alcoholism

         23. Those who are pregnant, nursing or expect to become pregnant over the course of the
             study

         24. Participating in another ongoing clinical trial

         25. Any other mental or physical condition which, in the opinion of the Investigator,
             makes the subject a poor candidate for clinical trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico de Obesidad</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore, Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

